Patient Case Studies

Consult these peer-guided patient case videos to help identify adult patients for whom XIFAXAN may be an appropriate therapy.

Management Considerations After an Overt HE Episode Featuring Rebecca McCollaum, NP

Overt Hepatic Encephalopathy Case Study Video, Susan

Management Considerations After an Overt HE Episode Featuring Rebecca McCollaum, NP

Follow along on the journey of Susan, who presents with a recurrent overt HE episode after being hospitalized for overt HE and requires improved management from her hepatologist.

Reducing the Risk of Recurrence Following an Overt HE Hospitalization Featuring Samantha Ramirez, NP-C

Overt Hepatic Encephalopathy Case Study Video, Carlos

Reducing the Risk of Recurrence Following an Overt HE Hospitalization Featuring Samantha Ramirez, NP-C

Follow along on the journey of Carlos, who was recently hospitalized for an overt HE episode and followed up with his primary care provider due to another episode.

Watch Video Download Case Study

Healthcare Professionals Sharing Clinical Insights

Join host Christina J. Hanson, FNP, in her conversations with fellow clinicians about clinical insights in the management of adult patients with overt hepatic encephalopathy (HE).

The Role of NPs and PAs in Supporting HE Patient Care Featuring Mikhail Alper, PA-C, California Gastroenterology Associates

Wistia video thumbnail
View transcript >

The Role of NPs and PAs in Supporting HE Patient Care Featuring Mikhail Alper, PA-C, California Gastroenterology Associates

All clinicians have a role in supporting the care of adults with overt hepatic encephalopathy (HE). Hear from fellow NPs and PAs about distinct opportunities you may have to support patients throughout their journeys.

Download podcast audio

Don’t have time to watch the full episode above? View the clip below.

The Importance of Recognizing Hepatic Encephalopathy in Your Cirrhosis Patients

Wistia video thumbnail

The Importance of Recognizing Hepatic Encephalopathy in Your Cirrhosis Patients

Management of Overt HEFeaturing Sharon Magalona, FNP-BC, Reddy GI Associates

Wistia video thumbnail

Management of Overt HEFeaturing Sharon Magalona, FNP-BC, Reddy GI Associates

Tune in to an overview about overt hepatic encephalopathy (HE) and learn about guideline recommendations and management for the reduction in risk of overt HE recurrence in adults.

Download podcast audio

Don’t have time to watch the full episode above? View clips below.

Assessing for HE in Patients With Cirrhosis

Wistia video thumbnail

Assessing for HE in Patients With Cirrhosis

Guideline Recommendation for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Wistia video thumbnail

Guideline Recommendation for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Helping Your Adult Patients With Overt HE Through Telehealth Featuring Sharon Magalona, FNP-BC, Reddy GI Associates

Wistia video thumbnail
View transcript >

Helping Your Adult Patients With Overt HE Through Telehealth Featuring Sharon Magalona, FNP-BC, Reddy GI Associates

The public health crisis with the pandemic has drastically altered how medicine is practiced and how care is provided. Find out how telehealth may help you and your patients with overt hepatic encephalopathy (HE) adapt and connect.

Download podcast audio

Don’t have time to watch the full episode above? View the clip below.

Assessing for Signs of Overt HE Through Telehealth

Wistia video thumbnail

Assessing for Signs of Overt HE Through Telehealth

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
    • HE (≥10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

SEE MORE

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.